| Category |
Mathematical & Computational Biology |
| Manuscript Type |
Minireviews |
| Article Title |
Pharmacophore approaches in protein kinase inhibitors design
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sergiy A Starosyla, Galyna P Volynets, Volodymyr G Bdzhola, Andriy G Golub and Sergiy M Yarmoluk |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Dr. Sergiy M Yarmoluk, Sci., Professor, Department of Medicinal Chemistry, Institute of Molecular Biology and Genetics, NAS of Ukraine, 150 Zabolotnogo St., 03680 Kyiv, Ukraine. sergiy@yarmoluk.org.ua |
| Key Words |
Protein kinase; Inhibitor; Pharmacophore model; Receptor-based method; Ligand-based method |
| Core Tip |
In the following review, we summarize the published data on pharmacophore models for inhibitors of tyrosine protein kinases (EGFR, HER2, VEGFR, JAK2, JAK3, Syk, ZAP-70, Tie2) and inhibitors of serine/threonine kinases (Clk, Dyrk, Chk1, IKK2, CDK1, CDK2, PLK, JNK3, GSK3, mTOR, p38 MAPK, PKB). Here, we have described the achievements of pharmacophore modeling for protein kinase inhibitors, which provide key points for further application of generated pharmacophore hypotheses in virtual screening, de novo design and lead optimization. |
| Publish Date |
2014-12-12 11:14 |
| Citation |
Starosyla SA, Volynets GP, Bdzhola VG, Golub AG, Yarmoluk SM. Pharmacophore approaches in protein kinase inhibitors design. World J Pharmacol 2014; 3(4): 162-173 |
| URL |
http://www.wjgnet.com/2220-3192/full/v3/i4/162.htm |
| DOI |
http://dx.doi.org/10.5497/wjp.v3.i4.162 |
